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Available online 01 June 2016Tuberculosis (TB), a disease caused by the human pathogenMycobacterium tuberculosis, recently joinedHIV/AIDS
on the top rank of deadliest infectious diseases. Low patient compliance due to the expensive, long-lasting and
multi-drug standard therapies often results in treatment failure and emergence of multi-drug resistant strains.
In this scope, antimicrobial peptides (AMPs) arise as promising candidates for TB treatment.
Herewe describe the ability of the exogenous AMP LLKKK18 to efﬁciently killmycobacteria. The peptide's poten-
tial was boosted by loading into self-assembling Hyaluronic Acid (HA) nanogels. These provide increased stabil-
ity, reduced cytotoxicity and degradability, while potentiating peptide targeting to main sites of infection. The
nanogels were effectively internalized by macrophages and the peptide presence and co-localization with
mycobacteria within host cells was conﬁrmed. This resulted in a signiﬁcant reduction of the mycobacterial
load inmacrophages infected in vitrowith the opportunisticM. avium or the pathogenicM. tuberculosis, an effect
accompanied by lowered pro-inﬂammatory cytokine levels (IL-6 and TNF-α). Remarkably, intra-tracheal admin-
istration of peptide-loaded nanogels signiﬁcantly reduced infection levels in mice infected withM. avium orM.
tuberculosis, after just 5 or 10 every other day administrations. Considering the reported low probability of resis-
tance acquisition, these ﬁndings suggest a great potential of LLKKK18-loaded nanogels for TB therapeutics.
© 2016 Elsevier B.V. All rights reserved.Keywords:
Antimicrobial peptide
Macrophages
Infectious diseases
Cathelicidin
Mycobacteria1. Introduction
Tuberculosis (TB) is a life-threatening disease caused byMycobacte-
rium tuberculosis. The World Health Organization recently reported
about 9.6 million TB cases in 2014, having its death toll increased to
around 1.5 million people, which places TB alongside HIV/AIDS as the
deadliest infectious diseases [1].
The emergence of multidrug-resistant TB (MDR-TB) strains at an es-
timated rate of 3.3% is a further concern. MDR-TB may bemostly attrib-
uted to the selection of drug resistance mutations resulting from
overuse and/or misuse of antibiotics. In addition, it has been demon-
strated that primary transmission of MDR strains plays an important
role in MDR-TB epidemics [2].
Tuberculosis transmission occursmostly via the respiratory tract [3].
Mycobacteria are then phagocytized by alveolar macrophages and
quickly spread across the lungs by lymphatic circulation. Weeks later,gama@deb.uminho.ptbacilli may disseminate from the lungs to highly irrigated organs such
as liver and kidneys [4,5]. Inside macrophages, mycobacteria are able
to multiply within phagosomes, provided they arrest the phagosome
maturation and its fusion with lysosomes, thereby avoiding contact
with potent hydrolytic enzymes and antigen-presenting organelles
present in the host macrophage [6,7].
TB control represents a major challenge. The only vaccine available,
Bacille Calmette-Guérin (BCG), successfully prevents childhood TB but
fails in protecting adults already infected or sensitized to mycobacteria
[8]. Standard chemotherapy for drug-susceptible TB consists in the ad-
ministration of a four antibiotic cocktail comprising isoniazid, rifampicin,
pyrazinamide and ethambutol over a 6-month period. The presence of
mycobacteria in stationary or low proliferating phases, as well as of mul-
tidrug-resistant strains, requires amoreprolonged treatment regimen, in-
volving the administration of pyrazinamide in combination with second-
line drugs (e.g. ﬂuoroquinolones, ethionamide, cycloserine, capreomycin
or prothionamide) that can last up to 24 months [9,10].
However, toxicity issues and elevated costs associated with these
drugs, as well as low patient compliance to the long-lasting regimens,
represent crucial drawbacks to the pharmacotherapy [11,12].
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tion of most drugs (usually within hours); 2) the systemic distribution
of drugs, in opposition to a more limited action upon their target cells
and tissues; 3) the limited bioavailability and poor absorption via specif-
ic routes (e.g. oral) [13,14]. As such, ﬁnding new treatments to improve
and shorten TB therapy, while comprising different action mechanisms
(less prone to resistance acquisition) has become imperative [15,16].
In this scope, antimicrobial peptides (AMPs) have gained interest as
promising candidates for the treatment of mycobacterial infections [17].
AMPs are typically cationic and amphipathic members of the innate im-
mune system, present in many living organisms. They usually comprise
a short amino acid chain (10–50 residues) and show a broader spectrum
of antimicrobial activity compared to standard antibiotics, often attribut-
ed to their non-speciﬁc killing mechanism [18,19]. Moreover, this non-
speciﬁcity, along with the high metabolic costs associated with resis-
tance-related mutations, is believed to have major implications in the re-
duced acquisition of AMP-resistance by mycobacteria [20,21].
The involvement of LL37, the only known human cathelicidin (a fam-
ily of AMPs), in the killing of mycobacteria within macrophages has al-
ready been reported [22]. An ongoing clinical trial (NCT01580007) has
evaluated the potential of the administration of 1,25-dihydroxyvitamin
D3 (vitamin D) and phenylbutyrate, as synergistic inducers of LL37 ex-
pression, to enhance intracellular mycobacteria killing inM. tuberculosis-
infected patients [23]. Several analogues of LL37 have also been
engineered to enhance its activity. In the 18-mer LLKKK18, the polar un-
charged residues glutamine and asparagine, and the negatively charged
aspartic acid, are substituted by positively charged lysines. This results
in a higher cationicity, hydrophobicity and ultimately higher antimicrobi-
al activity, when compared to LL37 [24,25]. Indeed, we recently demon-
strated LLKKK18 anti-mycobacterial activity against the opportunistic
Mycobacterium avium (M. avium) growing in axenic conditions [26].
However, it remains unknown whether this peptide is able to reduce
the mycobacterial load within infected macrophages or if it is active
against more virulent mycobacteria.
The use of drug delivery systems may help circumvent some issues
regarding the exogenous administration of AMPs, particularly by: 1)
speciﬁcally targeting the peptide to a particular organ, allowing co-lo-
calizationwith bacteria; 2) preventing degradation by proteases; 3) im-
proving stability and 4) increasing patient compliance through the
possible reduction of the administration period [27,28].
Recently, we developed self-assembling Hyaluronic acid (HA)
nanogels by grafting a hydrophobic molecule to HA [29]. The obtained
amphiphilic conjugates self-assemble in aqueous environments and
allow the entrapment of bioactive molecules in their hydrophobic
core. In normal physiological conditions, macrophages do not internal-
ize HA. However, Sladek and collaborators [30] showed that macro-
phages express the CD44 receptor in the beginning of an
inﬂammatory response. Since activated macrophages express CD44
and can internalize HA [31], these nanogels seem to be a promising op-
tion to deliver drugs to infected macrophages.
In this work we evaluated the potential of LLKKK18 to efﬁciently kill
the opportunistic M. avium and, most important, the human pathogen
M. tuberculosis, using both in vitro and in vivo models of infection. We
also hypothesized that the encapsulation of LLKKK18 into self-assem-
bling HA nanogels could boost the potential of LLKKK18 to treat pulmo-
nary mycobacterial infections, by enhancing the peptide's stability and
targeting to infected macrophages, while reducing systemic toxicity
and proteolytic degradability.
2. Materials and methods
2.1. Materials
Custom synthesis of LLKKK18 (KEFKRIVKRIKKFLRKLV)was obtained
from Schafer-N (Copenhagen, Denmark). Sodium hyaluronate
(7.46 kDa, 401 g/mol per disaccharide unit) was purchased fromLifecore Biomedical. AG 50W-X8 resin was acquired from Bio-Rad
(USA).
All other reagents, including tetrabutylammonium ﬂuoride
hydrate (TBA-F), 11-amino-1-undecanethiol hydrochloride (AT),
N-hydroxysulfosuccinimide (NHS) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) were
purchased from Sigma Aldrich (Barcelona, Spain), unless stated
otherwise.
2.2. Production of self-assembling hyaluronic acid-based nanogels
Production and characterization of self-assembling HA-based
nanogels were performed according to a previously described method
[29]. Firstly, a cationic exchange resin (AG 50W) was used to exchange
the cations of sodium hyaluronate with the lipophilic
tetrabutylammonium (TBA) ion, to enable HA solubilization in dimethyl
sulfoxide (DMSO). For this, 1 g AG 50W resinwasmixedwith 3.5 g TBA
in ultrapure water, for 1 h at room temperature, under mild stirring.
After washing and puriﬁcation, the resin was moved to a 1% (w/v) HA
solution in ultra-pure water and the ion exchange of TBA ions with HA
occurred for 2 h at room temperature, under mild stirring. The resin
was then removed by centrifugation (2 min, 5000 rpm) in a Sigma
113 centrifuge and the resulting supernatant (HA-TBA) freeze-dried.
Ion exchange was conﬁrmed by 1NMR spectroscopy. Crosslinking of
the hydrophobic 11-amino-1-undecanethiol (AT) was performed
through EDC/NHS chemistry [32]. The resulting solution was dialyzed
(MWCO 1000 Da) against 150 mM NaCl for 3 days to remove any re-
maining TBA ions and 2 days in distilled water to further remove NaCl.
Finally, the solution was freeze-dried and the resulting material (HA-
AT) stored at room temperature until further use.
2.3. Antimicrobial peptide encapsulation into HA-based nanogels
Peptide encapsulation efﬁciencywas quantiﬁed aftermixing 100 μM
LLKKK18 (Schafer-N, Denmark) with 0.5 mg/ml HA nanogels in Phos-
phate Buffered Saline (PBS) under mild rotation in a wheel, for 24 h at
room temperature. Unloaded peptide was removed by transferring
the solution into Amicon® Ultra-centrifugal ﬁlter units (Millipore)
with a molecular weight cut-off of 100 kDa and centrifugation for
2 min at 2000 rpm. The original volume in the concentrated solution
containing the peptide-loaded nanogels was then restored. The amount
of free and loaded LLKKK18was quantiﬁed by theWaddell method [33]
and the encapsulation efﬁciency was expressed as the percentage of
loaded peptide. Waddell's is a sensitive and accurate method for deter-
miningprotein concentration in a sample, based on the quantiﬁcation of
peptide linkages, thus not being affected by variations in protein com-
position and structure. Peptide concentration is calculated by
subtracting the absorbance reading at 225 nm from the 215 nm reading
and multiplying that difference by 0.144.
The peptide-nanogel solution was sterilized through ﬁltration using
a 0.22 μm polyethersulphone (PES) syringe ﬁlter.
For subsequent tests the amount of peptidemixedwith the nanogels
was set considering the observed encapsulation efﬁciency (around
70%). Formulations were stored at 4 °C for up to 1 month until they
were needed for further assays.
2.4. Characterization of the nanogels
Size distribution (diameter) and zeta potential of blank and peptide-
loaded nanogels were analyzed by Dynamic Light Scattering (DLS), as
previously described [29]. Brieﬂy, 1 ml of the blank or peptide-loaded
HA nanogels was dispersed in distilled water at 1 mg/ml and ﬁltered
with a 0.22 μm polyethersulfone (PES) syringe ﬁlter. LLKKK18 was en-
capsulated at the concentration used for the subsequent tests
(100 μM). The samples were then analyzed in a polystyrene cell or in a
folded capillary cell, for size distribution or zeta potential measurements,
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using a He-Ne gas laser (wavelength of 633 nm) and a detector angle of
173°. For each sample, the polydispersity index (PdI), z-average diameter
(corresponding to themean hydrodynamic diameter) and zeta potential
were evaluated after 6 repeated measurements. Zeta potential values
were determined using Henry's equation.2.5. Bacterial strains
The mycobacteria used in this study were selected based on their
virulence. Two strains of the opportunisticMycobacterium avium, 2447
and 25291, which form smooth transparent (SmT) colonies were ob-
tained from the American Type Culture Collection (ATCC, Manassas,
VA, USA). These strains were grown in Middlebrook 7H9 medium
(Difco, Sparks, MD) supplemented with Middlebrook Albumin, Dex-
trose, Catalase (ADC) Supplement (Sigma-Aldrich, Barcelona, Spain)
and 0.04% Tween 80, at 37 °C, according to the supplier's instructions.
For CFU counting, these strains were plated in solid Middlebrook
7H10 medium supplemented with Middlebrook Oleic acid, Albumin,
Dextrose, Catalase (OADC) Supplement (Sigma-Aldrich, Barcelona,
Spain) and 0.5% glycerol.M. tuberculosis H37Rv was obtained from the
Trudeau Institute Mycobacterial Collection and grown in conditions
similar to M. avium (Middlebrook 7H9 medium supplemented with
ADC and 0.04% Tween 80, at 37 °C), according to the supplier's instruc-
tions. Colony forming units (CFUs) were grown in Middlebrook 7H11
medium supplemented with 10% OADC (Sigma-Aldrich, Barcelona,
Spain) and 0.5% glycerol, at 37 °C.2.6. Anti-mycobacterial activity in axenic culture
Determination of the anti-mycobacterial activity of free and loaded
peptide was performed as previously described [26]. Frozen aliquots
ofM. avium 2447 orM. tuberculosis H37Rv were thawed and diluted in
7H9 broth medium supplemented with 10% ADC and 0.05% Tween 80
to attain a ﬁnal concentration of 2 × 104 CFU/ml and 50 μl of this culture
was added to a 96-well plate, in triplicate. Serial dilutions of the peptide
in distilled water, loaded or not into nanogels, were added to the
mycobacteria to a ﬁnal volume of 100 μl/well. Distilled water was
added to the control. The plate was then incubated in a humidiﬁed
chamber at 37 °C during 4 or 7 days (forM. tuberculosis orM. avium, re-
spectively) afterwhich the antimicrobial effectwas evaluated byplating
serial dilutions of the suspensions on solid Middlebrook 7H10 (M.
avium) or 7H11 (M. tuberculosis) agar medium supplemented with
10% OADC and 0.5% glycerol. CFUs in each plate were counted 1 or
3 weeks after plating, depending on the species. Mycobacterial survival
after 4 (M. tuberculosis) or 7 days (M. avium) of incubation was
expressed as a percentage relatively to a control group of mycobacteria
grown without LLKKK18. The concentration needed to reduceM. tuber-
culosis growth by 50% (IC50) was calculated from a dose-effect plot.2.7. Culture of murine bone marrow-derived macrophages
Bone marrow-derived cells (BMMΦ) from C57BL/6 mice were iso-
lated from femurs and tibia, removed under aseptic conditions, accord-
ing to a previously reportedmethod [34]. Bones were ﬂushed with 5ml
of Dulbecco's Modiﬁed Eagle's Medium (DMEM) supplemented with
10% Fetal Bovine Serum (FBS), passed through a cell strainer and centri-
fuged at 1200 rpm, 6 min, at 4 °C. The pellet was resuspended in 10 ml
DMEM supplemented with 20% L929-cell conditioned medium (LCCM)
and cells were allowed to differentiate into macrophages for 7 days in
100 mm diameter Petri dishes. Another 10 ml of DMEM containing
20% LCCM was added to the cells at day 4. At day 7, differentiated cells
were scraped from the Petri dishes and seeded at the desired concentra-
tion in 24 or 96 well plates.2.8. Viability and metabolic activity assays
2.8.1. MTS reduction test
The cells' metabolic activity in the presence of the LLKKK18-loaded
NPs was assessed by measuring the reduction of the tetrazolium salt
MTS (3-(4,5-dimethyl-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-
sulfophenyl)-2H tetrazolium). BMMΦ were seeded in 96-well plates
at 5 × 104 cells/well and allowed to adhere overnight. The cell culture
medium was then replaced by empty HA nanogels at different concen-
trations, prepared in DMEM to a ﬁnal volume of 200 μl. After 24 h, at 37 °
C, 5% CO2, 20 μl of MTS (CellTiter 96® Aqueous One Solution Cell Prolif-
eration Assay, Promega,WI, USA) was added per well and the plate was
further incubated for 2 h at 37 °C, protected from light, to allow the
formazan reduction to occur. Metabolic activity was then measured
spectrophotometrically at 490 nm in a Bio-RadModel 680 (Bio-Rad lab-
oratories, UK) microplate reader.
2.8.2. Trypan blue dye exclusion assay
BMMΦwere seeded in 96-well plates at the concentration of 5 × 104
cells/well. The cells were incubated for 24 h in the presence of the blank
and peptide-loaded NPs, in a ﬁnal volume of 100 μl/well. On the follow-
ingday, theplatewasplaced on ice for 1 h to detach BMMΦ, whichwere
then scraped andmixedwith Trypan blue (1:1) for cell counting using a
Neubauer Chamber. Trypan blue is only uptaked by cells with a
disrupted cellmembrane (non-viable), thus allowing the distinction be-
tween viable and non-viable cells.
2.8.3. Live/Dead assay
Cell viability was also assessed using the Live/Dead® Viability/Cyto-
toxicity Kit (Invitrogen, CA, USA), according to the manufacturer's in-
structions. BMMΦ were seeded in 96-well plates at 5 × 104 cells/well
and allowed to adhere overnight. The cell culture mediumwas then re-
placed by fresh culture medium, non-loaded (blank) or peptide-loaded
nanogels at the desired concentrations, and cells were incubated for
24 h at 37 °C, 5% CO2. Cell culture medium was then replaced by
100 μl of PBS containing 1 μM calcein AM and 2 μM ethidium homodi-
mer-1 (EthD-1) and incubated for 30 min at 37 °C, 5% CO2. Calcein-
AM and EthD-1 are indicators of intracellular esterase activity and plas-
mamembrane integrity, respectively. Cells were observed under a ﬂuo-
rescence microscope (Leica DMIRE2, with a DCF350FX camera) and
pictures taken from ﬁve random ﬁelds for each condition. The amount
of viable cells was expressed as a percentage relatively to a control
with no nanogels or peptide.
2.8.4. Apoptotic cell death detection
Evaluation of apoptotic cell deathwas performed using an in situ cell
death detection kit (Roche, UK), based on the Terminal
deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) assay.
BMMΦ were seeded on top of coverslips, in a 24-well plate, at 5 × 105
cells/well. InfectionwithM. aviumwas performed at amultiplicity of in-
fection (M.O.I.)=2 and both infected and non-infected cells were treat-
ed as described in the sections above. After 24 h, the cells were ﬁxed
using 2% paraformaldehyde (PFA) and TUNEL was applied according
to the manufacturer's instructions. The coverslips were observed
under a ﬂuorescencemicroscope (Leica DMIRE2,with a DCF350FX cam-
era) and at least 300 cells were counted per condition.
2.8.5. Free nitric oxide estimation
The accumulation of extracellular nitrites (NO2), an indicator of ni-
tric oxide synthase activity, was quantiﬁed by the Griess reaction, ac-
cording to a previously described protocol [35]. Nitrites react with
Griess reagent (1% sulfanilamide–0.1% naphthylethylenediamine
dihydrochloride in 5% concentrated H3PO4), forming a pink azo product
[36]. BMMΦ were seeded in 24-well plates at the concentration of
5 × 105 cells/well and further incubated for 24 h with blank and loaded
nanogels. NO2 accumulation was measured by mixing 50 μl of cell
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followed by an incubation period of 10 min at room temperature,
protected from light. Absorbance was measured at 550 nm in a micro-
plate reader and the nitrite concentration determined from a calibration
curve using sodium nitrite as a standard.
2.9. Intracellular effect of the nanogels on mycobacteria killing
The intracellular reduction of the mycobacterial burden was
assessed in BMMΦ infectedwith eitherM. avium 2447 orM. tuberculosis
H37Rv, as previously described [26]. BMMΦ were seeded at
5 × 105 cells/ml in 24-well plates, allowed to adhere overnight and in-
fected with either mycobacteria strain at a multiplicity of infection of
2 for 4 h to allow mycobacteria internalization. After that period, non-
internalized mycobacteria were removed by 4 washes in pre-warmed
DMEM and cells incubated with the blank or LLKKK18-loaded NPs. A
PBS solutionwas used as a control. After a 7- or 4-day incubation period,
for M. avium and M. tuberculosis, respectively, BMMΦ were perme-
abilized with saponin andmycobacteria survival was evaluated by plat-
ing serial dilutions on 7H11 agar plates. CFUs were then counted after
2 weeks of incubation at 37 °C, 5% CO2. The initial intracellular bacterial
burden was assessed identically at day 0. Of note, an independent re-
searcher additionally performed a blind experiment of the M. avium
assay.
2.10. Internalization studies
2.10.1. Confocal microscopy
M. avium strain 104 expressing recombinantGFP [37]wasused to vi-
sualize intracellular mycobacteria, similarly to a previously described
method [38]. BMMΦwere seeded at 5 × 105 cells/well in 24-well plates
with 12 mm diameter coverslips. Mycobacteria were added at a multi-
plicity of infection of 10 and, after 4 h, eachwellwas extensivelywashed
4 times with pre-warmed DMEM. Themacrophageswere then incubat-
ed for different time points with LLKKK18 andHA nanogels ﬂuorescent-
ly labeled with TAMRA (Schafer-N, Denmark) or Alexa Fluor 488,
respectively. Free LLKKK18was added at a concentration below the tox-
icity threshold (10 μM), whereas encapsulated LLKKK18 was added at
30 μM per well in 0.5 mg/ml HA nanogels. At the deﬁned endpoints,
cells were ﬁxed with 2% paraformaldehyde (in PBS) for 20 min and
the coverslip placed on top of a microscopy slide for observation
under a Confocal Scanning Laser Microscope (CLSM, Olympus BX61,
Model FluoView 1000), comprising a Laser DM 405/488/515/559/635
and the following emission ﬁlters: BA 505–540 (green channel), BA
575–620 (orange channel) and BA 655–755 (red channel). Images
were analyzed on the software FV10-ASW 4.2.
2.10.2. MALDI-ToF mass spectrometry
Internalization and intracellular degradation of LLKKK18 were also
assessed by Matrix-assisted laser desorption/ionization–time of ﬂight
(MALDI-ToF) mass spectrometry, according to a previously reported
protocol [39]. This method allows themeasurement of the total amount
of intact internalized peptide and the identiﬁcation of possible degraded
products. Brieﬂy, BMMΦ seeded at 5 × 105 cells/well in 12-well plates
were incubated (37 °C, 5% CO2) for different time points in the presence
of 5 μM (corresponding to 5 pmol/μl) of free or loaded peptide, contain-
ing an isotope tag of four non-deuterated glycines ([1H]LLKKK18,
Schafer-N, Denmark). Peptides were also biotinylated to facilitate ex-
traction, puriﬁcation, concentration and desalting, which was per-
formed with streptavidin-coated magnetic beads.
After the incubation period, cells were scraped and centrifuged for
2 min at 640 g in an Eppendorf® 5430R centrifuge (Eppendorf, NY,
USA) to recover intact cells. The pellet was further washed with 1 ml
Buffer A (50 mM Tris-HCl, (pH 7.4), 0.1 mg/ml Bovine Serum Albumin
(BSA)) and again centrifuged for 2 min at 640 g. 1 pmol of peptide
with four bi-deuterated glycines ([2H]LLKKK18) was then added tothe pellet and the cells were lysed for 15 min at 100 °C in the presence
of 150 μl lysis solution (0.3% Triton X-100, 1 M NaCl). The lysate was
centrifuged for 5 min at 12,000 g and 4 °C, and the supernatant trans-
ferred to a clean tube. The pellet was furtherwashedwith 850 μl of Buff-
er A, again centrifuged for 5 min at 12,000 g and 4 °C, and the
supernatant was combined with the previous one. A 10 μl solution of
washed streptavidin-coated magnetic beads (Dynabeads MyOne
Streptavidin C1, Invitrogen, UK) was added to the lysate and stirred
gently for 1 h at room temperature, to allow the binding of the beads
to the biotinylated peptides. The beads were then immobilized with a
Dynabeads® MPC®-S magnetic particle concentrator (Invitrogen, UK),
the supernatant was removed and the beads washed twice with
200 μl of Buffer A, twice with 200 μl of Buffer B (50 mM Tris-HCl,
(pH 7.4), 0.1 mg/ml BSA, 0.1% SDS), twice with 200 μl of Buffer C
(50 mM Tris-HCl, (pH 7.4), 0.1 mg/ml BSA, 1 M NaCl) and twice with
200 μl of distilled water. Saturation of the beads ensued, by incubating
them for 2 min with 400 pmol of biotin. The beads were then washed
with 50 μl of a 1:1 acetonitrile/water solution, and after removing that
solution, mixed with 5 μl of matrix (α-cyano-4-hydroxycinnamic acid
(CHCA) saturated solution in acetronitrile:0.1% TFA (1:1)). After mixing
the beads with CHCA matrix, 1 μl of each sample was spotted on the
MALDI sample holder. Mass spectra were acquired in a 4800 Plus
MALDI TOF/TOF Analyzer (Sciex, MA, USA) reﬂector positive mode for
the ranges m/z = 2750–2850 and m/z = 1000–3000. The obtained
mass spectra were internally calibrated for [1H]LLKKK18 at m/z =
2783.5 and [2H]LLKKK18 at m/z= 2791.5.
The area of the peaks of the [M+H]+ signals (including all isotopes)
of intact [1H]LLKKK18 and [2H]LLKKK18 was determined and the
amount of intact [1H]LLKKK18 was calculated from the area ratio.
2.11. Cytokines expression
Levels of Interleukin-6 (IL-6) and Tumor Necrosis Factor-α (TNF-α)
were determined by ELISpot (eBiosciences, Carlsbad, CA, USA) [40] in
infected and non-infected macrophages after incubation with the for-
mulations. Brieﬂy, BMMΦ seeded in 96-well plates at 5 × 104 cells/
well and allowed to adhere overnight. A part of the macrophages was
then infected with M. tuberculosis at a M.O.I. = 2 and both infected
and non-infected cells were incubated with either blank or peptide-
loaded nanogels. Peptide was loaded at a concentration of 100 μM.
PBS was added to the control group. At deﬁned time points, cell culture
mediumwas collected fromeachwell and50 μl of each condition placed
on 96-well plates previously coated with IL-6 or TNF-α antibodies
(eBiosciences, Carlsbad, CA, USA). Prior to the addition of the samples,
the antibody-coated platewaswashed and blocked for 1 h at room tem-
peraturewith 200 μl AssayDiluent. The antibodieswere then allowed to
bind the samples' proteins for 2 h at room temperature. The wells were
washed four times with PBS containing 0.05% Tween 80 and further in-
cubated with the secondary antibodies (1:100 dilution) for 1 h at room
temperature. Fifty μl of horseradish peroxidase-labeled avidin was then
added to thewells and the plate was incubated for 30min at room tem-
perature, protected from light. After thorough washing of the wells,
color development was achieved by adding 50 μl of 3,3′,5,5′-
Tetramethylbenzidine (TMB) to the wells and incubating the plate for
20 min, protected from light, after which the reaction was stopped by
addition of 25 μl of stop solution. Absorbance was measured at
450 nm in a Bio-Rad Model 680 (Bio-Rad laboratories, UK) microplate
reader and total protein expression levels determined from calibration
curves using standard concentrations of each protein.
2.12. In vivo assays
Female C57BL/6 mice aged 6–8 weeks were purchased from Charles
River Laboratories, Inc. (Barcelona, Spain) and housed at the ICVS ani-
mal facility under a 12 h dark/light cycle in a roomwith controlled tem-
perature and humidity. Standard chow and water were supplied ad
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peanUnionDirective 86/609/EEC andwere approved by the Portuguese
Veterinary authorities (Direção Geral de Veterinária).
Mice were infected aerogenically through exposure to an aerosol-
ized suspension of each mycobacteria strain mentioned in Section 2.5
for 40 min using a Glas-Col Inhalation Exposure System: a
2 × 106 CFU/ml suspension resulted in the implantation of ~20 CFU of
mycobacteria in the lungs of each mouse [41]. After 3 months to allow
the infection to reach a chronic stage, mice were anesthetized with an
intraperitoneal injection of ketamine (Imalgene®) and medetomidine
(Dorbene®).
HA nanogels were prepared at a concentration of 0.5 mg/ml and
administered either empty or loaded with 100 μM LLKKK18. PBS so-
lution was used as a control. Either 5 or 10 doses of the treatments
(50 μl each) were administered intra-tracheally every other day,
using a MicroSprayer® aerosolizer (IA-1C; Penn-Century, Philadel-
phia, PA, USA) attached to a high-pressure syringe (FMJ-250; Penn-
Century) [42]. The aerosol is generated through a sub-miniaturized
atomizer situated in the tip of a stainless steel tube, which is attached
to a hand-operated, high-pressure syringe. For administration, mice
were placed with their dorsa against an acrylic platform lifted at an
angle of about 45°. Mice were suspended with a rubber band by
their upper teeth and another rubber band was used to prevent lat-
eral movements during endotracheal administration. A lamp was
also used to provide proper illumination of the trachea. Blunted for-
ceps were used to help displace the tongue to allow proper oropha-
ryngeal exposure.
Mice were sacriﬁced by CO2 asphyxiation one week after the last
treatment and lungs were aseptically removed. The right superior lobe
was collected in 2% paraformaldehyde for histological analysis and the
remainder was homogenized in DMEM. A pre-treatment with collage-
nase (37 °C, 30 min) was applied to degrade the extracellular matrix
and saponin was ﬁnally added to the lung homogenate to release intra-
cellular mycobacteria. Serial dilutions were plated on Middlebrook
7H11 agar and CFUs were counted after about 1 or 3 weeks of incuba-
tion at 37 °C, depending on the species.
2.13. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
(GraphPad Software, La Jolla, CA). Normality of the distributionswas ex-
amined prior to each analysis using Kolmogorov-Smirnov and Shapiro-
Wilk normality tests, and taking into account the acceptability of skew-
ness and kurtosis values. According to the results from the normality
tests, one-way ANOVA, followed by a Newman-Keuls comparison
post-test was conducted wherever appropriate. A 95% conﬁdence inter-
val was considered as statistical signiﬁcant.
3. Results
3.1. Characterization of the nanogels
In this workwe used hydrophobized HA nanogels capable of self-as-
sembling in aqueous environments, which had been previously devel-
oped at our lab [29]. These nanogels allowed an encapsulation
efﬁciency of LLKKK18 of about 70%. We showed that at a concentration
of 0.5 mg/ml, the thyolated HA forms nanogels with a diameter of
133 ± 4 nm (Fig. 1A), with a polydispersity index (PDI) of 0.27 ±
0.02. An average zeta potential of−23.5 ± 0.5 mV was obtained (Fig.
1B), a value similar to the one presented by Pedrosa and co-workers
[29]. However, both size and zeta potential were signiﬁcantly altered
after loading of the nanogels with the positively charged LLKKK18
(Fig. 1A–B). Indeed, in the presence of the peptide, the average diameter
increases to 533 ± 13 nm, with a PDI of 0.1 ± 0.1. This small PDI indi-
cates that peptide loading resulted, remarkably, in a monomodal size
distribution, compared to the bimodal distribution of the emptynanogels. The presence of the peptide also resulted in a change in zeta
potential to 2.4 ± 0.1 mV, which may be attributed to the high
cationicity of the peptide (+8) and neutralization of the hyaluronic
acid negative charge [43].
Evaluation of the empty (non-loaded) nanogels effect on themacro-
phagesmetabolic activity was assessed using theMTS reduction test. As
observed in Fig. 1C, HA nanogels induce a dose-dependent decrease in
metabolic activity, showing a signiﬁcant reduction at 1.5 mg/ml. As
such, a concentration of 0.5 mg/ml HA nanogels was selected for subse-
quent assays.
3.2. Toxicity of LLKKK18-loaded nanogels towards BMMΦ
Two different methods were used to evaluate cell death caused by
the loaded nanogels: Live/Dead (Fig. 2A) and Trypan Blue Exclusion as-
says (Fig. 2B). Results from both assays revealed that loaded LLKKK18
did not cause BMMΦ death up to a 100 μM concentration, after 24 h
(Fig. 2A–B). These results are even more relevant considering that at
5 μM the free peptide reduced cell viability in about 21–26% and at
100 μMmore than 90% of the cells were non-viable.
Nevertheless, at 200 μM, loaded LLKKK18 induces a signiﬁcant de-
crease in cell viability, causing approximately 44% and 34% of cell
death, after the Live/Dead and Trypan blue assays, respectively.
Additionally, we observed no signiﬁcant effect in terms of the
number of apoptotic cells, regardless of the treatment or whether
the BMMΦ were or not infected with M. avium 2447 (Fig. 2C). We
also quantiﬁed the concentration of nitrites released to the cell cul-
ture medium by BMMΦ, as an indicator of reactive nitrogen species
(RNS) levels, in particular nitric oxide. These are commonly pro-
duced by macrophages as a way of coping with foreign particles or
microorganisms and may be deleterious to the cells themselves
[44]. Although the HA nanogels did not induce the overproduction
of NO2, a signiﬁcant increase in extracellular nitrites was found in
the presence of the peptide (Fig. 2D). Nevertheless, the nitrite con-
centration remained very low (less than 5 μM) as compared to
other reports of nitrite production by macrophages [45].
3.3. Mycobactericidal effect of LLKKK18
Previously, we reported that a LLKKK18 concentration of 58.81 ±
0.07 μM reduced the axenic growth ofM. avium to 50% [26]. Compared
with the MICs of standard antibiotics againstM. avium, this value (cor-
responding to about 135 μg/ml) may be considered high. Indeed, Heifets
and co-workers [46] reported MICs ranging between 0.6 and above
10 μg/ml for isoniazid, 0.12–16.0 μg/ml for rifampicin and 0.94–15 μg/ml
for ethambutol. Recently, Andrejak et al. [47] reported MICs of 8–N
16 μg/ml for rifampicin, 2–N4 μg/ml for clarithromycin and 16–32 μg/ml
for ethambutol. These authors also determined the MIC of combined
antibiotics, observing that, for example, the MIC of rifampicin lowered
from 16 μg/ml (alone) to 4 μg/ml when combined with ethambutol.
To evaluate if LLKKK18's effect remained after encapsulation in the
HA nanogels, axenic cultures ofM. aviumwere incubated with different
concentrations of peptide loaded in 0.5 mg/ml HA. It is worth noticing
that as the peptide is loaded into the HA nanogels, its readily available
concentration will not be as high as it would be expected from its free
(non-loaded) form. In this sense, it is reasonable to believe that a higher
concentration would be required to achieve similar results, hence the
increase in the concentration of loaded peptide. As observed in Fig. 3A,
the encapsulated AMP requires a higher dose (200 μM) to induce a sig-
niﬁcant reduction ofM. avium growth.
The effect of LLKKK18onmycobacteria residingwithinmacrophages
was further evaluated after incubating M. avium-infected BMMΦ for
7 days in the presence of the peptide-loaded nanogels.
Fig. 3B indicates that peptide-loaded nanogels resulted in the signif-
icant reduction of mycobacterial load within BMMΦ, being this effect
stronger for higher peptide concentrations. Indeed, approximately 1.9
Fig. 1. Characterization of the blank and LLKKK18-loaded HA nanogels. The effect of LLKKK18 encapsulation on average diameter size (A) and zeta potential (B). Assays were carried out
after overnight encapsulation of 100 μM LLKKK18 in a 0.5 mg/ml HA nanogel solution. Formulations were ﬁltered through a pore size of 0.22 μm prior to analysis. Both parameters were
measured in a Malvern Zetasizer. Values represent the mean ± SD (n = 6). *** p b 0.001, compared to blank nanogels. (C) Metabolic activity of BMMΦ in the presence of increasing
concentrations of empty HA nanogels, determined using the MTS reduction assay. Values represent the mean ± SEM, for at least 3 independent experiments performed in triplicates.
* p b 0.05, compared to control (cells alone).
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200 μM, respectively. Neither the free peptide nor empty nanogels had
any antimycobacterial effect on infected macrophages. Interestingly,Fig. 2. Cytotoxicity evaluation of the LLKKK18-containing formulations. BMMΦwere incubated
cytotoxicity of these nanogels was determined through different methods: plasma membra
quantiﬁcation of total number of apoptotic cells using the TUNEL-assay. Cells were either
production using Griess reaction. A combination of lipopolysaccharide (LPS) and interferon-γ
independent experiments performed in triplicates. * p b 0.05. *** p b 0.001, compared to respewhen added separately, LLKKK18 and nanogels yielded no
mycobacteria killing (Fig. 3C), leading to the conclusion that thenanogel
supports the targeted intracellular delivery of the peptide.in the presence of free peptide, as well as blank or peptide-loaded nanogels for 24 h and
ne integrity evaluated by (A) Live/Dead assay and (B) Trypan blue dye exclusion; (C)
infected (m.o.i. = 2) or non-infected with M. avium 2447; (D) Estimation of nitrite
(IFN-γ) was used as positive control. Columns represent the mean ± SEM, for at least 3
ctive controls. No statistically signiﬁcant differences were observed in the TUNEL assay.
Fig. 3. Activity of LLKKK18 againstM. avium. The efﬁcacy of LLKKK18 in suppressing the growth ofM. avium strain 2447 was ﬁrstly determined in axenic conditions, by adding it to the
culture either free or loaded into HA nanogels (A). Blank and peptide-loaded nanogels were also added toM. avium 2447-infected BMMΦ After 7 days, macrophages were lysed and
the number ofM. avium CFUs counted (B). BMMΦ were also incubated with 100 μM LLKKK18 and 0.5 mg/ml HA nanogels added separately, to ascertain a possible adjuvant effect of
the nanogels on LLKKK18 action (C). Data represents the mean ± SEM, for at least 3 independent experiments performed in triplicates. * p b 0.05. *** p b 0.001, compared to control.
Finally, the in vivo activity of LLKKK18-loaded nanogels was tested by administering them intra-tracheally (using a Microsprayer aerosolizer) to C57BL/6 animals infected with M.
avium strains 2447 (D) or the highly virulent 25921 (E). Therapy regimen consisted of 5 administrations (100 μM LLKKK18 in 0.5 mg/ml HA) every other day. A PBS solution was
administered to the control group. Data represents the mean ± SD, for at least 9 mice per group. *** p b 0.001, compared to control.
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tunisticM. avium strains 2447 and 25291 (highly virulent) was evaluat-
ed by treating infected mice after a 3-month infection settlement
period. Loaded nanogels were administered intra-tracheally 5 times
every other day and lungs were removed for CFU counting one week
after the last treatment.
Fig. 3D shows a signiﬁcant reduction (~1 log) of theM. avium 2447
load in the lungs of infected mice, a relevant decrease considering the
low concentration (100 μM, which corresponds to about 8 mg/kg) and
short therapy regimen applied. It should be noted that Bermudez et al.
[48] reported a signiﬁcant reduction ofM. avium in the lungs of infected
mice after the daily administration of 100mg/kg clarithromycin (a con-
centration 12.5 times higher than the one herein reported), during a 4-
week therapy. Similarly, Roque et al. [49] attained about 1-log reduction
in liver and spleen of infectedmice after 4weeks of therapy consisting on
the daily administration of three combined drugs at high concentrations
(4.67 mg/ml rifampicin, 22.5 mg/ml clarithromycin, and 2.92 mg/ml).
Since mycobacteria growth in untreated mice was not very high, we
also tested the effect of the peptide on the highly virulent M. avium
strain 25291. We expected that a larger mycobacterial growth would
allow the detection of a more pronounced effect of the peptide.However, as shown in Fig. 3E, both loaded and empty nanogels signiﬁ-
cantly reducedM. avium 25291 growth by about 0.3 log.3.4. Internalization and intracellular distribution of LLKKK18
BMMΦ were infected with anM. avium strain expressing recombi-
nant GFP [37] and further incubated with LLKKK18 tagged with a ﬂuo-
rescent red label (TAMRA) loaded into HA nanogels. Fig. 4A shows
that the loaded peptide uptake increases over time (up to 7 h), as indi-
cated by an increasing larger red area (peptide) in the cytoplasm. Most
important, it is possible to identify several situations in which the pep-
tide seems to co-localize with mycobacteria, as noted by the overlap-
ping of the ﬂuorescent labels (Fig. 4B). This suggests a possible direct
antimycobacterial effect of the peptide inside macrophages. Both pep-
tide and mycobacteria were detected throughout the cytosol, implying
that such co-localization may be non-speciﬁc. Using the 3.5 h time
point as an example, it was also possible to observe the uptake of free
peptide (Fig. 4C). However, as previously noted, the free peptide is not
able to reduce the infectionburden in themacrophages, again highlight-
ing the role of the nanogel as a targeting carrier.
Fig. 4. Internalization of LLKKK18 into macrophages. (A) BMMΦ were incubated with LLKKK18-loaded nanogels and at different timepoints, the internalization of the peptide was
ascertained by confocal microscopy. LLKKK18 was labeled with TAMRA (red) to allow its detection and BMMΦ nuclei were stained with DAPI (blue). (B) In addition to ﬂuorescently-
tagged LLKKK18, a GFP-expressing M. avium strain was used to observe the possible co-localization of the peptide with mycobacteria. Images shown in this condition were collected
after 7 h of incubation. (C) Free peptide also seemed to be internalized by macrophages, as it was detected intracellularly 3.5 h after its addition to the cells. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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fate inside the cell, this was further analyzed and quantiﬁed through
mass spectrometry (MS). MS spectra allowed the identiﬁcation of
LLKKK18 collected from lysed macrophages (Fig. 5A). The percentage
of intact peptide foundwithin the macrophages was estimated by com-
paring its peak area (m/z= 2783.5) with the peak area obtained for a
known amount of a bi-deuterated standard peptide (m/z = 2791.5),
added after cell lysis.Contrarily to what would be expected from the microscopy images,
we observed no signiﬁcant differences between the amount of internal-
ized intact LLKKK18 after 3.5 and 7 h of incubation. Noteworthy, at 7 h
MS spectra show some peaks with lower m/z than the intact peptide,
suggesting the presence of smaller peptide fragments (Fig. SI-1). Twen-
ty-four hours after addition of the loaded nanogels only small traces of
peptide were found inside macrophages. MS spectra also indicated
that free peptide enters BMMΦ. However, also in this case, the peaks
Fig. 5. Quantiﬁcation of intracellular intact peptide. BMMΦ were incubated in the
presence of a biotinylated version of the peptide, comprising an isotope tag of four non-
deuterated glycines ([1H]LLKKK18). These were added to cells either in a free form or
loaded into HA nanogels for different time periods. 1 pmol of an internal standard,
consisting of the peptide with four bi-deuterated glycines ([2H]LLKKK18) was added
after cell lysis. The percentage of intact LLKKK18 present intracellularly at each
timepoint was calculated from the area ratio obtained from the area of the peaks of the
[M+ H]+ signals (including all isotopes) of intact [1H]LLKKK18 and [2H]LLKKK18.
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is rapidly degraded inside macrophages.
3.5. LLKKK18 effect on pro-inﬂammatory cytokines expression
Cathelicidins like LL37 and its analogues have been associated with
immunomodulatory properties [50]. Here we analyzed the effects on
the expression of two cytokines, IL-6 and TNF-α, which play a key role
in the immune response to infection. IL-6 expression was increased in
the control (non-treated) BMMΦ 24 h after infection withM. tuberculo-
sis (Fig. 6A). The expression of this cytokine then decreased over time
up to 72 h. However, in the presence of the HA nanogels, IL-6 levels
were signiﬁcantly lower than in the control at 24 h. A further reduction
in this cytokine expression to non-detectable levels was induced by the
presence of LLKKK18. In fact, IL-6 expression is not detected at any time
point in the presence of the peptide, similarly to what is observed in
non-infected BMMΦ.
Similarly, no TNF-α expression was identiﬁed at any timepoint or at
any condition in the non-infected cells (Fig. 6B). Also in accordancewith
the IL-6 results, the nanogel containing the peptide induced a signiﬁcant
decrease in TNF-α levels over time to almost basal values. However, it
appears that the HA nanogel stimulated an increase of this cytokine,
being statistically signiﬁcant compared to the untreated control, at 24 h.
3.6. Peptide-loaded nanogel action on M. tuberculosis
Fig. 7A shows that free LLKKK18 leads to a dose-dependent reduc-
tion of M. tuberculosis load growing in axenic cultures. The MinimumFig. 6. Cytokine expression onM. tuberculosis-infected BMMΦ treated with LLKKK18-loaded n
incubated in the presence of blank or peptide-loaded nanogels for 72 h. The expression leve
mean ± SD, for at least 3 independent experiments. * p b 0.05, ** p b 0.01, *** p b 0.001, compInhibitory Concentration (MIC50), i.e. the peptide concentration
resulting in a 50% mycobacteria growth reduction, was estimated to
be 49.23 ± 5.44 μM, slightly lower than the one previously obtained
for M. avium 2447 (58.81 ± 0.07 μM) [26]. Once again, these values
(corresponding to about 114 μg/ml) are higher than the ones previously
reported for conventional antibiotics against M. tuberculosis: 0.025–
0.05 μg/ml for isoniazid, b100 μg/ml for pyrazinamide, 0.06–0.25 μg/
ml for rifampicin and 0.94–3.8 μg/ml for ethambutol [46]. However,
higher MIC values have been reported for other peptides. For example,
MIC values of 300 and 1200 μg/ml have been reported for MIAP and
Magainin-1, respectively [51]. Azurocidin has been reported to kill 55%
ofM. tuberculosisH37Rv at 100 μg/ml [52]. Also, theM(LLKK)2Mpeptide
series presented a MIC of 125 μg/ml [16].
Also in a similar fashion to what occurred with M. avium strains,
100 μM LLKKK18-loaded nanogel reduced (~1.5 log) theM. tuberculosis
load within infected BMMΦ (Fig. 7B). Moreover, treatment ofM. tuber-
culosis-infected mice with the peptide-containing nanogel resulted in a
signiﬁcant effect of LLKKK18 against these pathogenic mycobacteria
(Fig. 7C). Two different therapy regimens were tested, comprising ei-
ther 5 or 10 administrations of the peptide-nanogel formulations, ad-
ministrated every other day. Results in Fig. 7C show that the shorter
therapy with the nanogel alone induced a decrease in mycobacteria
levels, whereas this effect disappears for a longer administration regi-
men. Nevertheless, the shorter peptide-nanogel regimen led to a 0.7-
log reduction in mycobacteria levels, signiﬁcantly different from the
nanogel alone. This effect was further augmented to ~1.2-log decrease
(p b 0.01) by doubling the number of administrations.
Histology sections of the lung tissues do not show any visible differ-
ences between the different treatment conditions (HA alone and pep-
tide-loaded nanogel) in terms of lesion extent and severity, although
there seems to be an improvement regarding the number and size of
granulomas relatively to the non-treated tissues (Fig. 8).
4. Discussion
Despite the plethora of applications provided by antimicrobial pep-
tides, their use in the biomedical ﬁeld is often disregarded due to toxic-
ity, stability and solubility issues [53]. In the present work, we
encapsulated the LL37's analogue LLKKK18 in self-assembling HA
nanogels previously developed by our group [29]. This loading resulted
in increased average particle size and neutralization of the HA anionic
charge. The cationicity and hydrophobicity of the peptide may act as a
driving force leading to its encapsulation within the hydrophobic core
of the negatively charged nanogel. Such encapsulationmay, at least par-
tially, account for the increase in the average diameter of the particles,
as a similar event has been reported with insulin-loaded poly(lactide-
co-glycolide) nanoparticles [54]. On the other hand, it is possible that
the increase in particle size upon peptide loading reﬂects the formation
of self-assembling macromolecular micelles. Although they might un-
dergo extrusion upon ﬁltration, they re-assemble afterwards to reachanogel. BMMΦ were infected or not withM. tuberculosis H37Rv (M.O.I. = 2) and further
ls of (A) IL-6 and (B) TNF-α were measured using an ELISA assay. Data represents the
ared to control (PBS). +++ p b 0.001, compared to HA.
Fig. 7. Activity of LLKKK18 againstM. tuberculosis H37Rv. (A) Dose-response curve demonstrating the ability of LLKKK18 to directly suppress the growth of M. tuberculosis in axenic
conditions, after 4 days. (B) Blank and peptide-loaded nanogels (containing 100 μM LLKKK18) were added to M. tuberculosis-infected BMMΦ. After 4 days, cells were lysed and the
number of mycobacteria CFUs counted. Data represents the mean ± SEM, for at least 3 independent experiments performed in triplicates. * p b 0.05, compared to control (PBS). (C)
The in vivo activity of LLKKK18-loaded nanogels was ultimately tested in C57BL/6 animals infected with M. tuberculosis. The treatments were administered intra-tracheally using a
Microsprayer aerosolizer. Therapy regimens with the nanogel consisted of either 5 or 10 administration, every other day. A PBS solution was administered to the control group. Data
represents the mean ± SD, for 6–9 mice per group. ** p b 0.01, *** p b 0.001, compared to control (PBS) with respective number of administrations. + p b 0.05, +++ p b 0.001,
compared to HA with respective number of administrations.
121J.P. Silva et al. / Journal of Controlled Release 235 (2016) 112–124an equilibrium state at a particle size of 500 nm. Nevertheless, it
should be noted that this is a highly reproducible process, as indicat-
ed by the small error bars and low polydispersity index (0.1 ± 0.1).
The neutralization of the net electrical charge produced by the pep-
tide suggests the binding of LLKKK18 to the surface of the nanogel.
Altogether, peptide-induced modiﬁcations may be advantageous,
as uptake by macrophages is enhanced for particles larger than
0.5 μm [55,56], and charge neutralization may decrease the nanogels
cytotoxicity (known to increase in the presence of charged - espe-
cially anionic - nanoparticles) [57,58]. Moreover, the particles size
distribution becomes monomodal in the presence of the peptide,
resulting in more homogeneous emulsions.
Nagaoka and colleagues [59] reported the toxicity of free LLKKK18 in
peritoneal macrophages and RAW 264.7 cells at concentrations above
10 μg/ml (approximately 4.3 μM). Indeed, herewe showed that a similar
concentration (5 μM) of free peptide reduced the viability of bonemar-
row-derivedmacrophages in 21–26% and that at 100 μM, almost all cells
were non-viable. However, we also demonstrated that LLKKK18 loaded
into the nanogel displayed no cytotoxic effects, in terms of intracellular
esterase activity and plasma membrane integrity, up to 100 μM (more
than 23-fold the toxic concentration reported for free peptide). This is
a relevant result, as we clearly show that peptide loading into the HA
nanogels overcomes one of the major problems associated with the ex-
ogenous administration of these peptides.
Up to this concentration, the total number of apoptotic cells also
remained at basal levels. Nevertheless, a slight nitric oxide production
was observed in the presence of the peptide. Indeed, reactive nitrogen
species (RNS), like •NO, are usually produced by macrophages as away of eliminating invading bacteria [44], suggesting that this •NO in-
duction by the peptide may contribute to the increased
mycobactericidal activity.
Taken together, the modiﬁcations in particle size, charge and cyto-
toxicity proved important to facilitate the intracellular delivery of the
peptide to macrophages. Although the uptake of HA should not be ex-
pected from macrophages in normal physiological conditions, we ob-
served that infected macrophages successfully internalized this
nanogel. The overexpression of the CD44 receptor by activated macro-
phages, previously reported by Underhill and co-workers [31], might
positively inﬂuence the nanogel uptake. Most importantly, the nanogel
facilitated the peptide targeting to mycobacteria residing within intra-
cellular compartments. Such targeting assumes great relevance consid-
ering themodiﬁcations in vacuolar trafﬁcking that allow themasking of
mycobacteria within macrophages [6] and potentiates a direct killing
mechanism. The detection of both peptide and mycobacteria through-
out the cytoplasm suggests that the co-localization of peptide with
mycobacteria may be non-speciﬁc. However, additional experiments
will be required to ﬁnd any co-localization in speciﬁc intracellular
compartments.
Most importantly, in vitro incubation of macrophages with
LLKKK18-loaded nanogel reduced the intracellular levels of both M.
avium andM. tuberculosis. These results strengthen the importance of
using a proper carrier to deliver anti-TB drugs. Indeed, despite its uptake
by cultured macrophages, free LLKKK18 failed to reach mycobacteria
and reduce infection levels, which is in accordance with previous
work regarding the induction of intracellular overexpression of its mu-
rine counterpart cRAMP [26].
Fig. 8. Representative histology images of lung sections stainedwith hematoxylin & eosin. At the end of the in vivo experiments withM. tuberculosis, mice were sacriﬁced, lungs removed
and ﬁxed in 3.7% formaldehyde. Lungs were then sectioned and stainedwith hematoxylin and eosin. (A) Non-infected; (B) 3-month infection (before the beginning of the treatments; (C)
PBS, 10 administrations; (D) HA nanogels, 10 administrations; (E) LLKKK18-loaded nanogels, 10 administrations.
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ticular standard antibiotics, the concentration of LLKKK18herein reported
to inhibit 50% of mycobacteria growthmay be considered high. However,
is not uncommon to ﬁnd some variability among MIC values for a drug
against the same mycobacterial strain. This is the case of rifampicin,
whose MIC againstM. aviummay range from 0.03 μg/ml [60] to 0.5 μg/
ml [61]. Differences in terms of methodologies may account for this vari-
ability and include: 1) the use of different strains (some aremore suscep-
tible/resistant than others); 2) the method used to determine the MIC
(e.g. resazurin, which gives an indication of the cells metabolic activity
vs CFU counting, which correlates with total bacteria number); 3) testing
conditions (e.g. initial inoculum, culture media, incubation period). This
variability is further noticed in in vivo testing. Parameters like administra-
tion route, dose regimen (concentration and frequency), period post-in-
fection or initial inoculum greatly inﬂuence the outcome of infection
and make it difﬁcult to compare different studies.
It is also relevant noting that diminished levels of two pro-inﬂamma-
tory cytokines, IL-6 and TNF-α, accompanied the decrease ofM. tubercu-
losis load in infected macrophages treated with HA + LLKKK18. IL-6, in
particular, may be considered a potent biomarker of mycobacterial infec-
tion due to its in vitro overexpression in mycobacteria-infected cells [62].
Moreover, our data on TNF-α expression is consistent with previousﬁndings using LL37 [63] and further support the modulation of macro-
phages response to infection by cathelicidins. Considering the key role
of these two cytokines in stimulating the immune response during infec-
tion [64,65], a decrease in their expression levels may indeed be associat-
ed with the reduced mycobacterial load within macrophages.
It has been long known that results obtained in vitro for anti-TB
drugs may not exactly match their efﬁcacy in vivo [66,67]. This was
not the case with LLKKK18-loaded nanogel, as the peptide induced a
signiﬁcant decrease of the mycobacterial burden in mice infected with
mycobacteria of different virulence and pathogenicity.
Some discrepancies were observed regarding the mycobactericidal
activity against the twoM. avium strains tested, with a higher effect dur-
ingM. avium 2447 infection. The growth of this strain is arrested as a re-
sult of both innate and adaptive immune mechanisms whereas M.
avium 25291, known for its higher virulence, continues to proliferate
until it eventually kills the animal [68,69]. In view of the fact that one
of the major issues related with the failure of some anti-TB drugs, in-
cluding the standard antibiotic isoniazid, is their inefﬁcacy against
mycobacteria in stationary phase or with very low proliferating rates
[70], these results are unexpected. Two different hypothesis may help
explain such ﬁndings: 1) M. avium 25291 may be more resistant to
the peptide; 2) despite same inoculum and peptide concentration
123J.P. Silva et al. / Journal of Controlled Release 235 (2016) 112–124were used, the every other day therapy regimen gives time for the
mycobacteria that are not eliminated to continue proliferating. In this
sense, it is reasonable to expect only a slight reduction of M. avium
25291 burden.
Most importantly, a signiﬁcant reduction in mycobacterial levels was
found in the lungs of mice infected with M. tuberculosis after treatment
with peptide-loaded nanogel. This effect appeared to be dose-dependent,
as doubling the number of administrations resulted in a more pro-
nounced reduction of the bacterial load, reaching levels below the ones
observed before the beginning of the treatment. Of note, administration
of empty HA nanogels also reduced the infection levels in mice infected
with eitherM. tuberculosis (only after 5 doses of HA) orM. avium 25291.
This is not completely unexpected, as the CD44 receptor has been report-
ed tomediate the entry ofmycobacteria intomacrophages [71]. The inter-
action of HA with CD44 receptors may thus block the entry of newly
proliferating bacteria or prevent the activation of pathways that may
lead to the induction of residing mycobacteria proliferation, in similar
fashion to what has been described in Listeria monocytogenes [72].
Although MIC values obtained in axenic conditions may not be con-
sidered very impressive, the observed LLKKK18-induced reduction of
themycobacterial load in infectedmacrophages and in infected animals
is of great relevance. Achieving a ~1.2-log reduction in M. tuberculosis
levels in the lungs of infected mice is per se an important result, consid-
ering that: the peptide-loaded nanogels were administered only 10
times (every other day); and the therapy comprised a single bioactive
molecule, contrasting with the standard multiple drug regimens. De
Groote and co-workers [41] evaluated the outcome of the 6-month
standard drug regimen of isoniazid, rifampicin and pyrazinamide. The
authors showed that it takes that long period, with daily administra-
tions of the three drugs combined, to achieve a complete elimination
of the infection. Additionally, the authors showed that even after
6 months a combination of pyrazinamide and rifampicin only resulted
in a 2-log reduction. Kalita et al. [73] reported the effect of a combined
therapy of isoniazid and rifampicin, administered daily during 4–
6 weeks, against M. tuberculosis. According to that study, when both
drugs were administered at 12.5 mg/kg/day, using the referred therapy
regimen, less than 1-log reductionwas attained. Doubling of both drugs
concentration to 25 mg/kg/day only resulted in an overall reduction of
mycobacterial load in mice lungs of about 1.5-log.
Having attained such an effect with LLKKK18 in particular is even
more relevant taking into consideration that previous experiments com-
prising the induction of intracellular overexpression of LL37 (LLKKK18's
“parent” peptide) failed to eliminate mycobacteria within host macro-
phages, as it was rapidly cleared from the intracellular milieu [26].
Moreover, it is reasonable to expect that optimization of the formula-
tion may result in higher efﬁcacy, while reducing peptide concentration
and dosage regimen. Such optimization will be important to reduce the
costs of production, which are currently higher than the $19–22 required
for a standard antibiotic therapy of 6 months [11]. Nevertheless, costs as-
sociatedwith the 24-month,multiple antibiotic therapies required for the
treatment of multidrug-resistant tuberculosis remain elevated (ranging
between $4000–6000). Although further studies need to be performed,
given the lower probability of mycobacteria acquiring resistance to
AMPs as compared to antibiotics, due to their non-speciﬁc killing mecha-
nism [18,19], these LLKKK18-loaded nanogels may assume particular in-
terest for the treatment of multidrug- (MDR) or extremely drug-
resistant (XDR) forms of tuberculosis, as well as atypical mycobacterioses
showing resistance to conventional therapies.
5. Conclusions
Administration of LLKKK18 loaded into self-assembling hyaluronic
acid nanogels holds promising indications as a novel method to treat
mycobacterial infections. The nanogel target the peptide towards the
main infected sites, while boosting its potential by: 1) allowing the
use of high therapeutic doses; 2) facilitating peptide uptake by infectedmacrophages; 3) stabilizing the peptide within their hydrophobic core;
and 4) reducing proteolytic degradation.
Long-term and expensive standard therapies based onmultiple drug
cocktails often result in low patient compliance, with subsequent emer-
gence ofmultidrug-resistant strains and proliferation of the disease. Our
data thus suggest that LLKKK18-loaded nanogel may hold great poten-
tial as an alternative approach to control tuberculosis and other
mycobacterioses, ﬁnding particular interest for treatment of antibiotic-
resistant forms.
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